



TML: CS: BSE/NSE CORR: 2022-23

17th February, 2023

The Manager
Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051

Scrip Code – 530199

Symbol: THEMISMED

Sub: Press Release

Ref: 1. Regulation 30 of the SEBI (LODR) Regulations, 2015
2. BSE Scrip Code: 530199
3. NSE Scrip Code: THEMISMED

Dear Sir/Madam,

In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a copy of the press release titled - **Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing.**

Kindly take this on record.

Thanking you,

Yours faithfully,

For Themis Medicare Ltd.

Sangameshwar Iyer
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India
***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621
Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat
CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219
***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com

PRESS NOTE CONTENT

Mumbai, India: 16 February, 2023

Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing.

In a landmark development for Themis Medicare Ltd (Themis), the Company has received approval from Drug Controller General of India (DCGI) for import & marketing of *Remifentanil 1 mg/2mg Powder for Concentrate for Solution for Injection*. The drug been approved for use (1) as an analgesic agent for use during the *induction and maintenance of general anesthesia for inpatient and outpatient procedures*, (2) for continuation as an *analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting*, and (3) as an analgesic component of *monitored anesthesia care* in adult patients.

Themis will market this drug with the brand name **REMITHEM[®]**.

Remifentanil is short-acting narcotic analgesic with a rapid onset & rapid offset of action that offers easy dose titration, predictable and precise intraoperative control, and reduced or rapidly reversed side effects. Due to its distinct pharmacokinetic and pharmacodynamic properties and rapid extra-hepatic clearance, Remifentanil has several applications in general anesthesia and in intensive care where rapid clearance of drug is beneficial.

Remifentanil was – first approved by USFDA in 1996. With the current approval in India, the long wait for the *rapid acting narcotic analgesic* is over. REMITHEM[®] will be imported by Themis and marketed in India soon by its well-trained sales team which is currently marketing a range of anesthesia and critical care products to hospitals across the country.

With a strong R&D backup, skilled domestic & export teams, and state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs and REMITHEM[®] approval is yet another step in this direction.

About Themis Medicare Ltd.

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma companies specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug- delivery systems, the Company has evolved into being a formidable player in the complex generics space. It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs – 1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis Medicare offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectable portfolio and develop its NDDS presence.